TG Therapeutics, Inc. Q2 2026 Earnings Recap

Shares dropped 6.3% following the quarter as investors reacted negatively to a cautious outlook and the implied challenges expanding beyond the core BRIUMVI IV franchise, despite steady commercial execution and pipeline progress.

Key Takeaways

• BRIUMVI sales continued to grow, approaching a $1 billion annualized run rate with expanding physician adoption and new patient starts.
• Positive Phase III ENHANCE data supported a simplified single-infusion initiation, potentially easing patient and provider burden by mid-2027.
• Subcutaneous BRIUMVI showed promising Phase I bioavailability data; Phase III results are expected late this year or early next, with the subcutaneous formulation poised to roughly double the addressable market.
• Early-stage expansion efforts include Phase I in myasthenia gravis and Phase II initiation in treatment-resistant schizophrenia, though these remain speculative and modest investments.
• The cautious tone around broader franchise growth, timing uncertainties around subcutaneous data, and exploratory pipeline projects likely tempered enthusiasm, contributing to the stock’s material decline.